Evidence map›Paper›PMID 28604744›Full record

ArticleOncogene2017

EMP2 is a novel therapeutic target for endometrial cancer stem cells.

M H Kiyohara, C Dillard, J Tsui, S R Kim, J Lu, D Sachdev, L Goodglick, M Tong, V F Torous, C Aryasomayajula and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. EMP3: A promising biomarker for tumor prognosis and targeted cancer therapy.Cancer biomarkers : section A of Disease markers · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

M H KiyoharaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
C DillardDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J TsuiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
S R KimDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J LuCenter to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA, USA.
D SachdevDepartment of Internal Medicine David Geffen School of Medicine at UCLA Los Angeles, CA, USA.
L GoodglickDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
M TongDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
V F TorousDepartment of Pathology and Laboratory Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
C AryasomayajulaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
W WangDepartment of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
P NajafzadehDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
L K GordonDepartment of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J BraunDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
S McDermottMedical Oncology, University of Michigan, Ann Arbor, MI, USA.
M S WichaMedical Oncology, University of Michigan, Ann Arbor, MI, USA.
M WadehraDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of Michigan–Ann Arbor · USBeth Israel Deaconess Medical Center · USCharles R. Drew University of Medicine and Science · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
Training and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5M
The Early Detection Research Network Biomarker Resource Laboratory at UCLAU24CA086366 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S. · 2000 to 2014
$7.3M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR000124NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA163971NCI NIH HHS U24 CA086366NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931
6 · The paper itself

Abstract

Previous studies have suggested that overexpression of the oncogenic protein epithelial membrane protein-2 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from disease. To understand the role of EMP2 in the etiology of disease, gene analysis was performed to show transcripts that are reciprocally regulated by EMP2 levels. In particular, EMP2 expression correlates with and helps regulate the expression of several cancer stem cell associated markers including aldehyde dehydrogenase 1 (ALDH1). ALDH expression significantly promotes tumor initiation and correlates with the levels of EMP2 expression in both patient samples and tumor cell lines. As therapy against cancer stem cells in endometrial cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor formation using xenograft HEC1A models was determined. Anti-EMP2 IgG1 reduced the expression and activity of ALDH and correspondingly reduced both primary and secondary tumor load. Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells.

Indexed as

Aldehyde Dehydrogenase 1 FamilyAnimalsBiomarkers, TumorCarcinogenesisCell Line, TumorEndometrial NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunoglobulin GIsoenzymesMembrane GlycoproteinsMiceMice, Inbred BALB CMice, NudeAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanALDH1A1 protein, mouseBiomarkers, TumorEMP2 protein, humanImmunoglobulin GIsoenzymesMembrane GlycoproteinsRetinal Dehydrogenase

Identifiers

PMID28604744
PMCPMC5648618
OpenAlexW2625922353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.